Search Results - "DUDEK, Arkadiusz"

Pericytes and vessel maturation during tumor angiogenesis and metastasis by Raza, Ahmad, Franklin, Michael J., Dudek, Arkadiusz Z.

“…Despite promising results in preclinical and clinical studies, the therapeutic efficacy of antiangiogenic therapies has been restricted by a narrow focus on…”
Get full text

Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases by Mittapalli, Rajendar K, Vaidhyanathan, Shruthi, Dudek, Arkadiusz Z, Elmquist, William F

“…Brain metastases are a common cause of death in stage IV metastatic melanoma. Dabrafenib is a BRAF (gene encoding serine/threonine-protein kinase B-Raf)…”
Get more information

Immune Checkpoint Inhibitor Therapy for Kidney Transplant Recipients - A Review of Potential Complications and Management Strategies by Barbir, Elena Bianca, Abdulmoneim, Samer, Dudek, Arkadiusz Z, Kukla, Aleksandra

“…Immune checkpoint inhibitor (ICI) therapy has enabled a paradigm shift in Oncology, with the treatment of metastatic cancer in certain tumor types becoming…”
Get full text

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial by Yang, James Chih-Hsin, Prof, Shih, Jin-Yuan, MD, Su, Wu-Chou, Prof, Hsia, Te-Chun, MD, Tsai, Chun-Ming, Prof, Ou, Sai-Hong Ignatius, MD, Yu, Chung-Jen, Prof, Chang, Gee-Chen, MD, Ho, Ching-Liang, MD, Sequist, Lecia V, MD, Dudek, Arkadiusz Z, MD, Shahidi, Mehdi, MD, Cong, Xiuyu Julie, PhD, Lorence, Robert M, MD, Yang, Pan-Chyr, Prof, Miller, Vincent A, Dr

“…Summary Background Afatinib is an irreversible ErbB-family blocker with preclinical activity in non-small-cell lung cancer (NSCLC) with EGFR mutations. We…”
Get full text

Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies by Danciu, Oana C., Holdhoff, Matthias, Peterson, Richard A., Fischer, James H., Liu, Li C., Wang, Heng, Venepalli, Neeta K., Chowdhery, Rozina, Nicholas, M. Kelly, Russell, Meredith J., Fan, Timothy M., Hergenrother, Paul J., Tarasow, Theodore M., Dudek, Arkadiusz Z.

“…Background Procaspase-3 (PC-3) is overexpressed in multiple tumour types and procaspase-activating compound 1 (PAC-1) directly activates PC-3 and induces…”
Get full text

Computational methods in developing quantitative structure-activity relationships (QSAR): a review by Dudek, Arkadiusz Z, Arodz, Tomasz, Gálvez, Jorge

“…Virtual filtering and screening of combinatorial libraries have recently gained attention as methods complementing the high-throughput screening and…”
Get more information

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial by Forde, Patrick M., Anagnostou, Valsamo, Sun, Zhuoxin, Dahlberg, Suzanne E., Kindler, Hedy L., Niknafs, Noushin, Purcell, Thomas, Santana-Davila, Rafael, Dudek, Arkadiusz Z., Borghaei, Hossein, Lanis, Mara, Belcaid, Zineb, Smith, Kellie N., Balan, Archana, White, James R., Cherry, Christopher, Ashok Sivakumar, I. K., Shao, Xiaoshan M., Chan, Hok Yee, Singh, Dipika, Thapa, Sampriti, Illei, Peter B., Pardoll, Drew M., Karchin, Rachel, Velculescu, Victor E., Brahmer, Julie R., Ramalingam, Suresh S.

“…Mesothelioma is a rare and fatal cancer with limited therapeutic options until the recent approval of combination immune checkpoint blockade. Here we report…”
Get full text

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma by Dudek, Arkadiusz Z., Zolnierek, Jakub, Dham, Anu, Lindgren, Bruce R., Szczylik, Cezary

“…BACKGROUND: Sunitinib and sorafenib are small‐molecule tyrosine kinase inhibitors (TKI) with antitumor activity in advanced renal cell carcinoma. A…”
Get full text

ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study by Johnson, Melissa, Dudek, Arkadiusz Z, Sukari, Ammar, Call, Justin, Kunk, Paul R, Lewis, Karl, Gainor, Justin F, Sarantopoulos, John, Lee, Patrice, Golden, Adele, Harney, Allison, Rothenberg, S Michael, Zhang, Yuanyuan, Goldman, Jonathan W

“…ARRY-382 (PF-07265804) is a selective inhibitor of colony-stimulating factor-1 receptor. We evaluated the safety and preliminary efficacy of ARRY-382 plus…”
Get full text

Sphingosine-1-Phosphate Receptor 1 Activity Promotes Tumor Growth by Amplifying VEGF-VEGFR2 Angiogenic Signaling by Balaji Ragunathrao, Vijay Avin, Anwar, Mumtaz, Akhter, Md Zahid, Chavez, Alejandra, Mao, De Yu, Natarajan, Viswanathan, Lakshmikanthan, Sribalaji, Chrzanowska-Wodnicka, Magdalena, Dudek, Arkadiusz Z., Claesson-Welsh, Lena, Kitajewski, Jan K., Wary, Kishore K., Malik, Asrar B., Mehta, Dolly

“…The vascular endothelial growth factor-A (VEGF-A)-VEGFR2 pathway drives tumor vascularization by activating proangiogenic signaling in endothelial cells (ECs)…”
Get full text

Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003 by Dudek, Arkadiusz Z, Liu, Li C, Gupta, Shilpa, Logan, Theodore F, Singer, Eric A, Joshi, Monika, Zakharia, Yousef N, Lang, Joshua M, Schwarz, James K, Al-Janadi, Anas, Alva, Ajjai S

“…We hypothesized that bevacizumab will potentiate activity of pembrolizumab. We conducted a phase Ib/II, single-arm, multisite clinical trial of the combination…”
Get full text

Two Malignancies With Differential Responses to Immune Checkpoint Inhibitors: A Case Report by Han, Se Young, Jahagirdar, Balkrishna N, Dudek, Arkadiusz Z

“…Immune checkpoint inhibitors (ICI) have changed the management of cancer dramatically. However, not all patients respond to ICI and their use places patients…”
Get full text

Endothelial Expression of Endothelin Receptor A in the Systemic Capillary Leak Syndrome by Sek, Albert C, Xie, Zhihui, Terai, Kaoru, Long, Lauren M, Nelson, Celeste, Dudek, Arkadiusz Z, Druey, Kirk M

“…Idiopathic systemic capillary leak syndrome (SCLS) is a rare and potentially fatal vascular disorder characterized by reversible bouts of hypotension and edema…”
Get full text

A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction by Zylla, Dylan M., Eklund, Justin, Gilmore, Grace, Gavenda, Alissa, Guggisberg, Jordan, VazquezBenitez, Gabriela, Pawloski, Pamala A., Arneson, Tom, Richter, Sara, Birnbaum, Angela K., Dahmer, Stephen, Tracy, Matthew, Dudek, Arkadiusz

“…Purpose The prevalence of medical cannabis (MC) use in patients with cancer is growing, but questions about safety, efficacy, and dosing remain. Conducting…”
Get full text

Management of Resistance to EGFR TKI-Targeted Therapy of Lung Cancer: Lessons in Monitoring Cancer Evolution by Dudek, Arkadiusz Z

Get more information

Intrinsic endothelial hyperresponsiveness to inflammatory mediators drives acute episodes in models of Clarkson disease by Ablooglu, Ararat J, Chen, Wei-Sheng, Xie, Zhihui, Desai, Abhishek, Paul, Subrata, Lack, Justin B, Scott, Linda A, Eisch, A Robin, Dudek, Arkadiusz Z, Parikh, Samir M, Druey, Kirk M

“…Clarkson disease, or monoclonal gammopathy-associated idiopathic systemic capillary leak syndrome (ISCLS), is a rare, relapsing-remitting disorder featuring…”
Get full text

Inhibition of mesothelin as a novel strategy for targeting cancer cells by Wang, Kun, Bodempudi, Vidya, Liu, Zhengian, Borrego-Diaz, Emma, Yamoutpoor, Farnaz, Meyer, Anna, Woo, Richard A, Pan, Weihong, Dudek, Arkadiusz Z, Olyaee, Mojtaba S, Esfandyari, Tuba, Farassati, Faris

“…Mesothelin, a differentiation antigen present in a series of malignancies such as mesothelioma, ovarian, lung and pancreatic cancer, has been studied as a…”
Get full text

CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma by Price, Matthew A., Colvin Wanshura, Leah E., Yang, Jianbo, Carlson, Jennifer, Xiang, Bo, Li, Guiyuan, Ferrone, Soldano, Dudek, Arkadiusz Z., Turley, Eva A., McCarthy, James B.

“…Summary Chondroitin sulfate proteoglycan 4 (CSPG4), a transmembrane proteoglycan originally identified as a highly immunogenic tumor antigen on the surface of…”
Get full text

Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901 by Dudek, Arkadiusz Z., Wang, Xiaofei, Gu, Lin, Duong, Stephanie, Stinchcombe, Thomas E., Kratzke, Robert, Borghaei, Hossein, Vokes, Everett E., Kindler, Hedy L.

“…The role of maintenance therapy for malignant pleural mesothelioma (MPM) is unknown. We performed a randomized phase II trial to determine if continuation of…”
Get full text

Profound impairment of adaptive immune responses by alkylating chemotherapy by Litterman, Adam J, Zellmer, David M, Grinnen, Karen L, Hunt, Matthew A, Dudek, Arkadiusz Z, Salazar, Andres M, Ohlfest, John R

“…Overall, cancer vaccines have had a record of failure as an adjuvant therapy for malignancies that are treated with alkylating chemotherapy, and the…”
Get full text